Literature DB >> 15864538

The influence of type 2 diabetes on fibrin structure and function.

E J Dunn1, R A S Ariëns, P J Grant.   

Abstract

AIMS/HYPOTHESIS: The precise mechanisms underlying the increased risk of cardiovascular disease (CVD) in type 2 diabetes are unclear. Fibrin clot structure has been related to CVD risk in the general population. We therefore assessed this in type 2 diabetic patients as a potential mechanism whereby diabetes influences CVD risk.
METHODS: Fibrin clots were formed from fibrinogen purified from 150 subjects with type 2 diabetes and varying degrees of glycaemic control (assessed by HbA1c), and from 50 matched control subjects. Clot structure was assessed by turbidity, permeation and confocal microscopy. The specific effect of glucose itself was assessed by analysing the structure of clots formed from purified fibrinogen in the presence of increasing concentrations of the sugar.
RESULTS: Clots formed by fibrinogen purified from type 2 diabetic subjects had a denser, less porous structure than those from control subjects. The structural changes found were related to the individual's glycaemic control; HbA1c correlated negatively with permeation coefficient (Ks) values (indicates clot pore size) (r = -0.57, p < 0.0001) and positively with maximum absorbance (indicator of fibre size) (r = 0.33, p < 0.0001), branch point number (r = 0.78, p < 0.0001) and fibre density (r = 0.63, p < 0.0001). The ambient glucose level influenced clot structure; hypo- (< 5 mmol) and hyperglycaemia (> or = 10 mmol/l) were both associated with a reduction in Ks values and maximum absorbance, and with increased fibre density and branch point number within clots. CONCLUSIONS/
INTERPRETATION: The structural differences found to occur in type 2 diabetes and in association with hypo- and hyperglycaemia may confer increased resistance to fibrinolysis, and in consequence contribute to the increase in CVD risk in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864538     DOI: 10.1007/s00125-005-1742-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  46 in total

1.  Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.

Authors:  J P Collet; D Park; C Lesty; J Soria; C Soria; G Montalescot; J W Weisel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  The effect of fibrin structure on fibrinolysis.

Authors:  D A Gabriel; K Muga; E M Boothroyd
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

3.  Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Diabetes       Date:  1983-07       Impact factor: 9.461

Review 4.  Fibrinogen and fibrin.

Authors:  R F Doolittle
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

5.  Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.

Authors:  W B Kannel; R B D'Agostino; P W Wilson; A J Belanger; D R Gagnon
Journal:  Am Heart J       Date:  1990-09       Impact factor: 4.749

6.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

7.  Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation.

Authors:  E Shacter; J A Williams; R L Levine
Journal:  Free Radic Biol Med       Date:  1995-04       Impact factor: 7.376

8.  Non-enzymatic glucosylation of fibrinogen.

Authors:  B A McVerry; S Thorpe; F Joe; P Gaffney; E R Huehns
Journal:  Haemostasis       Date:  1981

9.  The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris.

Authors:  P M Zack; T Ischinger; U T Aker; B Dincer; H L Kennedy
Journal:  Am Heart J       Date:  1984-12       Impact factor: 4.749

10.  Glycosylation of human fibrinogen in vivo.

Authors:  A Lütjens; A A te Velde; E A vd Veen; J vd Meer
Journal:  Diabetologia       Date:  1985-02       Impact factor: 10.122

View more
  47 in total

1.  Differences in coagulation between hemodialysis and peritoneal dialysis.

Authors:  Donald F Brophy; Daniel E Carl; Bassem M Mohammed; Jingmei Song; Erika J Martin; Jessica L Bostic; Todd W B Gehr
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

2.  Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls.

Authors:  Alison J Dawson; Thozhukat Sathyapalan; Peter Sedman; Ramzi Ajjan; Eric S Kilpatrick; Stephen L Atkin
Journal:  Obes Surg       Date:  2014-03       Impact factor: 4.129

3.  Nanoparticle diffusion measures bulk clot permeability.

Authors:  Richard Chasen Spero; Rachel K Sircar; Ryan Schubert; Russell M Taylor; Alisa S Wolberg; Richard Superfine
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

4.  Experimental and imaging techniques for examining fibrin clot structures in normal and diseased states.

Authors:  Natalie K Fan; Philip M Keegan; Manu O Platt; Rodney D Averett
Journal:  J Vis Exp       Date:  2015-04-01       Impact factor: 1.355

5.  Smoking out the cause of thrombosis.

Authors:  Robert A Campbell; Kellie R Machlus; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01       Impact factor: 8.311

Review 6.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

7.  Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.

Authors:  E J Dunn; H Philippou; R A S Ariëns; P J Grant
Journal:  Diabetologia       Date:  2006-03-16       Impact factor: 10.122

Review 8.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

Authors:  R J King; P J Grant
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

9.  Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model.

Authors:  Marlien Pieters; Namukolo Covic; Francois H van der Westhuizen; Chandrasekaran Nagaswami; Yelena Baras; Du Toit Loots; Johann C Jerling; Dale Elgar; Kathryn S Edmondson; Danie G van Zyl; Paul Rheeder; John W Weisel
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

10.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.